The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan

References

• Taiwan Cancer Registry. http://tcr.cph.ntu.edu.tw/main.php?Page =N2. Accessed 2016
   Google Scholar
• Health Promotion Administration, Ministry of Health and Welfare. http://www.hpa.gov.tw/English/ClassPrint.aspx?No =201401280006. Accessed 2016
   Google Scholar
• Xiong W, Zeng ZY, Xia JH et al A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res 2004;64:1972-4
   PubMed Web of Science ®Google Scholar
• Chie WC, Chang SH, Huang CS et al. () Prognostic factors for the survival of Taiwanese breast cancer patients. J Formos Med Assoc 2002;101:98-103
   PubMed Web of Science ®Google Scholar
• Cheng SH, Tsou MH, Liu MC, et al. Unique features of breast cancer in Taiwan. Breast Cancer Res Treat 2000;63:213-23
   PubMed Web of Science ®Google Scholar
• Lee JH, Yim SH, Won YJ, et al. Population-based breast cancer statistics in Korea during 1993-2002: incidence, mortality, and survival. J Korean Med Sci 2007;22(Suppl):S11
   Google Scholar
• Minami Y, Tsubono Y, Nishino Y, et al. The increase of female breast cancer incidence in Japan: emergence of birth cohort effect. Int J Cancer 2004;108:901-6
   PubMed Web of Science ®Google Scholar
• The Research Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1994: estimates based on data from seven population-based cancer registries. Jpn J Clin Oncol 1999;29:361-4
   PubMed Web of Science ®Google Scholar
• O'Sullivan CC, Bradbury I, Campbell C, et al. Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors ≤2 cm: a meta-analysis of the randomized trastuzumab trials. J Clin Oncol 2015;33:2600-8
   PubMed Web of Science ®Google Scholar
• Seferina SC, Lobbezoo DJ, de Boer M, et al. Real-life use and effectiveness of adjuvant trastuzumab in early breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. Oncologist 2015;20:856-63
   PubMed Web of Science ®Google Scholar
• Negri E, Zambelli A, Franchi M, et al. Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study. Oncologist 2014;19:1209-15
   PubMed Web of Science ®Google Scholar
• van Rooijen JM, de Munck L, Teeuwen GM, et al. Use of trastuzumab for HER2-positive metastatic breast cancer in daily practice: a population-based study focusing on the elderly. Anticancer Drugs 2016;27:127-32
   PubMed Web of Science ®Google Scholar
• Leung HW, Chan AL. Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data. Expert Opin Drug Saf 2015;14:1661-71
   PubMed Web of Science ®Google Scholar
• Mantarro S, Rossi M, Bonifazi M, et al. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med 2016;11:123-40
   PubMed Web of Science ®Google Scholar
• Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 2000;9:235-51
   PubMed Web of Science ®Google Scholar
• Statistics times: International Monetary Fund World Economic Outlook (April-2015). http://statisticstimes.com/economy/projected-world-gdp-capita-ranking.php. Accessed October 24, 2015
   Google Scholar
• Dedes KJ, Szucs TD, Imesch P, et al. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol 2007;18:1493-9
   PubMed Web of Science ®Google Scholar
• Essers BA, Seferina SC, Tjan-Heijnen VC, et al. Transferability of model-based economic evaluations: the case of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer in the Netherlands. Value Health 2010;13:375-80
   PubMed Web of Science ®Google Scholar
• Hall PS, Hulme C, McCabe C, et al. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence. Pharmacoeconomics 2011;29:415-32
   PubMed Web of Science ®Google Scholar
• Hedden L, O'Reilly S, Lohrisch C, et al. Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. Oncologist 2012;17:164-71
   PubMed Web of Science ®Google Scholar
• Purmonen TT, Pänkäläinen E, Turunen JH, et al. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol 2011;50:344-52
   PubMed Web of Science ®Google Scholar
• Lidgren M, Wilking N, Jönsson B, et al. Health related quality of life in different states of breast cancer. Quality Life Res 2007;16:1073-81
   PubMed Web of Science ®Google Scholar
• Skedgel C, Rayson D, Younis T. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial. Value Health 2009;12:641-8
   PubMed Web of Science ®Google Scholar
• Chen W, Jiang Z, Shao Z, et al. An economic evaluation of adjuvant trastuzumab therapy in HER2-Positive early breast cancer. Value Health 2009;12(3 Suppl):S82-S4
   Google Scholar
• Shiroiwa T, Fukuda T, Schimozuma K, et al. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat 2008;109:559-66
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr, Lubeck D, Lalla D, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 2007;110:489-98
   PubMed Web of Science ®Google Scholar
• Buendía JA, Vallejos C, Pichón-Rivière A. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia. Biomedica 2013;33:411-17
   PubMed Web of Science ®Google Scholar
• Beauchemin C, Letarte N, Mathurin K, et al. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada. J Med Econ 2016;5:1-24
   Google Scholar